4D Molecular Therapeutics (FDMT) Return on Capital Employed Growth (1y) (2022 - 2026)
4D Molecular Therapeutics (FDMT) Return on Capital Employed Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 1,648.00 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 31,429.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1,805.00 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2,503.00 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -105.00 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -3,457.00 |
| 10 | 4D Molecular Therapeutics | 691.54 Mn | 300.64 Mn | - | 361.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 361.00 |
| Dec 31, 2025 | -138.00 |
| Sep 30, 2025 | -2,706.00 |
| Jun 30, 2025 | -2,623.00 |
| Mar 31, 2025 | -1,397.00 |
| Dec 31, 2024 | 5.00 |
| Sep 30, 2024 | 206.00 |
| Jun 30, 2024 | 1,962.00 |
| Mar 31, 2024 | 2,126.00 |
| Dec 31, 2023 | 909.00 |
| Sep 30, 2023 | 719.00 |
| Jun 30, 2023 | -716.00 |
| Mar 31, 2023 | -2,218.00 |
| Dec 31, 2022 | -1,769.00 |
| Sep 30, 2022 | -982.00 |
| Jun 30, 2022 | -1,349.00 |
| Mar 31, 2022 | -239.00 |